Kymera Therapeutics (NASDAQ:KYMR) Price Target Cut to $134.00 by Analysts at BTIG Research

Kymera Therapeutics (NASDAQ:KYMR) had its target price decreased by analysts at BTIG Research from $138.00 to $134.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price points to a potential upside of 46.42% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Stifel Nicolaus set a $114.00 price objective on Kymera Therapeutics in a research note on Monday, December 8th. Mizuho lifted their target price on Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Bank of America raised their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Wells Fargo & Company lifted their price objective on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $117.55.

Kymera Therapeutics Trading Up 0.9%

KYMR stock traded up $0.84 during midday trading on Thursday, hitting $91.52. 578,276 shares of the company’s stock were exchanged, compared to its average volume of 765,381. The firm has a 50 day moving average price of $78.07 and a 200-day moving average price of $64.68. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $103.00. The stock has a market capitalization of $6.58 billion, a price-to-earnings ratio of -25.49 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.88) earnings per share. On average, sell-side analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.76, for a total transaction of $448,800.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $86.00 per share, with a total value of $172,499,918.00. Following the completion of the purchase, the director owned 7,955,916 shares in the company, valued at $684,208,776. This represents a 33.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 450,895 shares of company stock valued at $40,486,151 in the last ninety days. Insiders own 16.01% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Baker BROS. Advisors LP raised its position in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. raised its stake in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the period. Finally, Holocene Advisors LP purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at $47,563,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.